Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsBristol Myers Squibb maintains strong positions in oncology and neuroscience with high free cash flow generation.
Investors in the healthcare sector frequently compare the merits of industry giants like Bristol Myers Squibb (BMY) and Pfizer (PFE), especially considering their dividend yields and drug pipelines. Both companies stand to be affected by patent expirations of their flagship drugs. Bristol Myers Squibb concentrates on enhancing its existing strengths in specialized oncology and immunology, while Pfizer is leveraging its substantial cash reserves accumulated during the pandemic to enter emerging, high-growth therapeutic sectors.
Bristol Myers Squibb is dedicated to developing groundbreaking therapies for severe diseases, with a primary emphasis on oncology, hematology, and neuroscience. The company's latest annual report, filed with the SEC, underscored its leadership in cancer treatment. Bristol Myers Squibb maintains strategic alliances with Merck (MRK) and Zai Lab (ZLAB) to develop a range of products.
The company has recently concluded its manufacturing collaboration with Cellares, aiming to streamline its production processes. Bristol Myers Squibb distributes its treatments via direct sales teams and partnerships with international distributors.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
